Sophie Willis
- Indexed articles, last 90 days
- 9
- Latest publication
- Sep 29, 2026
- Outlet visibility, for The Pharmaceutical Journal
- Top 1M sites
- Earliest in this view
- Jul 6, 2026
Latest articles
The lives cut short by medicine shortages (opens the original)
Read excerpt
With pharmaceutical companies sending an average of four medicine shortage warnings to the government each day, the issue of drug supply has a tight grip over the NHS and its patients. June 2026 saw a record number of price concessions, which can indicate shortages, issued by the government at 254 — breaching the 250 mark for the first time. In addition, a House of Lords committee report, published in February 2026, labelled medicines shortages a “national security issue”, stating that ministers
GLP-1s: what is behind the variation in efficacy? (opens the original)
Read excerpt
Since the approval of semaglutide (Wegovy; Novo Nordisk) as a weight-loss injection in the United States in 2021, the effect of GLP-1 medicines on the treatment of obesity has been undeniable. In the UK alone, it is estimated that 8 million adults have taken or are considering taking a GLP-11. Following the arrival of Wegovy tablets in June 2026 — and more oral GLP-1s on the horizon — this impact could be even greater. However, studies have shown variation in the efficacy of GLP-1s across sex,
Everything you need to know about clinical trial legislation changes (opens the original)
Read excerpt
On 28 April 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) and Health Research Authority introduced what they described as “the largest package of reforms in over 20 years” for clinical trials that will mean “patients benefit from earlier access to the latest innovative medicines”. The reforms allow for faster set-up of low-risk trials and modification to pre-existing trials to be approved quicker, as well as the use of early data from overseas studies and computer model si
Coroner raises concerns over lack of national guidance on prescribing for hepatitis B reactivation (opens the original)
Read excerpt
A coroner has raised concerns over a lack of national guidance on prescribing and monitoring for hepatitis B reactivation, following the death of a patient. In a ‘Prevention of future deaths’ report‘, published online on 10 July 2026, Richard Brittain, assistant coroner for Inner London North, stated that patient Tung Tran, aged 41 years, died from complications from reactivation of hepatitis B, “which arose from inadvertent discontinuation of necessary medical treatment”. Tran had a renal trans
Royal college president named pharmacist of the year at Black Healthcare Awards (opens the original)
Read excerpt
Tase Oputu, president of the Royal College of Pharmacy, has been named ‘Pharmacist of the Year’ at the Black Healthcare Awards 2026. The award, presented by the Caribbean and African Health Network (CAHN) at a ceremony held on 4 July 2026 in London, was given to Oputu for her “leadership, commitment to tackling health inequalities and contribution to advancing the pharmacy profession”. She was jointly awarded the honour with pharmacist Yeyenta Osasu, national pharmacy integration lead at NHS Eng
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 1M sites
For The Pharmaceutical Journal, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.